Centre for Nutrition, Department of Clinical Medicine, University of Bergen, 5009 Bergen, Norway.
Division of Gastroenterology, Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway.
Nutrients. 2019 Jul 17;11(7):1635. doi: 10.3390/nu11071635.
Peptides from fish may beneficially affect several metabolic outcomes, including gut health and inflammation. The effect of fish peptides in subjects with irritable bowel syndrome (IBS) has not previously been investigated, hence this study aimed to evaluate the effect of a cod protein hydrolysate (CPH) supplement on symptom severity, gut integrity markers and fecal fermentation in IBS-patients. A double-blind, randomized parallel-intervention with six weeks of supplementation with 2.5 g CPH ( = 13) or placebo ( = 15) was conducted. The outcomes were evaluated at baseline and the end of the study. The primary outcomes were symptom severity evaluated by the IBS severity scoring system (IBS-SSS) and quality of life. The secondary outcomes included gut integrity markers and pro-inflammatory cytokines in serum, fecal fermentation measured by concentration of short-chain fatty acids (SCFAs) and fecal calprotectin. The groups were comparable at baseline. The total IBS-SSS-scores were reduced in both the CPH-group (298 ± 69 to 236 ± 106, = 0.081) and the placebo-group (295 ± 107 to 202 ± 103, = 0.005), but the end of study-scores did not differ ( = 0.395). The concentrations of serum markers and SCFAs did not change for any of the groups. The baseline measures for the whole group showed that the total SCFA concentrations were inversely correlated with the total IBS-SSS-score ( = -0.527, = 0.004). Our study showed that a low dose of CPH taken daily by IBS-patients for six weeks did not affect symptom severity, gut integrity markers or fecal fermentation when compared to the placebo group.
鱼肽可能对多种代谢结果有益，包括肠道健康和炎症。以前尚未研究过鱼肽对肠易激综合征 (IBS) 患者的影响，因此本研究旨在评估鳕鱼蛋白水解物 (CPH) 补充剂对 IBS 患者的症状严重程度、肠道完整性标志物和粪便发酵的影响。进行了为期六周的双盲、随机平行干预，补充 2.5 克 CPH（n = 13）或安慰剂（n = 15）。在基线和研究结束时评估结果。主要结局是通过 IBS 严重程度评分系统 (IBS-SSS) 和生活质量评估的症状严重程度。次要结局包括血清中的肠道完整性标志物和促炎细胞因子、通过短链脂肪酸 (SCFA) 浓度测量的粪便发酵以及粪便钙卫蛋白。两组在基线时具有可比性。CPH 组（298 ± 69 至 236 ± 106， = 0.081）和安慰剂组（295 ± 107 至 202 ± 103， = 0.005）的总 IBS-SSS 评分均降低，但研究结束时的评分无差异（ = 0.395）。任何一组的血清标志物和 SCFA 浓度均未改变。整个组的基线测量结果表明，总 SCFA 浓度与总 IBS-SSS 评分呈负相关（ = -0.527， = 0.004）。我们的研究表明，IBS 患者每天服用低剂量的 CPH 六周，与安慰剂组相比，不会影响症状严重程度、肠道完整性标志物或粪便发酵。
